Treating osteomyelitis: Antibiotics and surgery

Plastic and Reconstructive Surgery

Volumn 127, Issue SUPPL. 1 S, 2011, Pages

  Rao, Nalini ^a   Ziran, Bruce H ^a   Lipsky, Benjamin A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ALGORITHM; BIOFILM; DIABETIC FOOT; DRUG EFFECT; HUMAN; OSTEOMYELITIS; REVIEW;

ALGORITHMS; ANTI-BACTERIAL AGENTS; BIOFILMS; DIABETIC FOOT; HUMANS; OSTEOMYELITIS;

EID: 78651329240     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3182001f0f     Document Type: Article

References (58)

1. Mader JT, Ortiz M, Calhoun JH. Update on the diagnosis and management of osteomyelitis. Clin Podiatr Med Surg. 1996; 13:701-724.
2. Mader JT, Shirtliff ME, Bergquist SC, Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clin Orthop Relat Res. 1999;360:47-65.
3. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:369-379.
4. Mackowiak PA, Jones SR, Smith JW. Diagnostic value of sinus-tract cultures in chronic osteomyelitis. JAMA. 1978; 239:2772-2775.
5. Howard CB, Einhorn M, Dagan R, Yagupski P, Porat S. Fineneedle bone biopsy to diagnose osteomyelitis. J Bone Joint Surg Br. 1994;76:311-314.
6. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol. 1995;49:711-745.
7. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998;280:295-298.
8. Lynch AS, Abbanat D. New antibiotic agents and approaches to treat biofilm-associated infections. Expert Opin Ther Pat. 2010;20:1373-1387.
9. Dell'Acqua G, Giacometti A, Cirioni O, et al. Suppression of drug-resistant staphylococcal infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. J Infect Dis. 2004; 190:318-320.
10. Cirioni O, Giacometti A, Ghiselli R, et al. Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rate pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides. Circulation 2003;108:767-771.
11. Balaban N, Collins IV, Cullor JS, et al. Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides 2000;21:1301-1311.
12. Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sörgel F. Penetration of antibacterials into bone: Pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48:89-124.
13. Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother. 2010; 65:1252-1257.
14. Byren I, Peters EJG, Hoey C, Berendt A, Lipsky BA. Pharmacotherapy of diabetic foot osteomyelitis. Expert Opin Pharmacother. 2009;10:3033-3047.
15. McKinnon PS, Davis SL. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis. 2004;23:271-288.
16. Jacobs MR. Optimization of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589-596.
17. Andes D, Craig WA. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clin North Am. 1998;12:849-860, vi.
18. Fraimow HS. Systemic antimicrobial therapy in osteomyelitis. Semin Plast Surg. 2009;23:90-99.
19. Perencevich EN, Kaye KS, Strausbaugh LJ, Fisman DN, Harris AD. Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: A survey of infectious diseases consultants. Clin Infect Dis. 2004;38:476-482.
20. Levison ME. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am. 2004;18:451-465, vii.
21. Karamanis EM, Matthaiou DK, Moraitis LI, Falagas ME. Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: A meta-analysis of randomized controlled trials. Spine (Phila Pa 1976) 2008;33:E297-E304.
22. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: A systematic review of the literature. Arch Intern Med. 2008;168:805-819.
23. Osmon DR, Berbari EF. Outpatient intravenous antimicrobial therapy for the practicing orthopaedic surgeon. Clin Orthop Relat Res. 2002;403:80-86.
24. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy: DSA guidelines. Clin Infect Dis. 2004;38:1651-1672.
25. Sia IG, Berbari EF, Karchmer AW. Prosthetic joint infections. Infect Dis Clin North Am. 2005;19:885-914.
26. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: What have we learned from 30 years of clinical trials? Int J Infect Dis. 2005;9:127-138.
27. Buchholz HW, Engelbrecht H. [Depot effects of various antibiotics mixed with Palacos resins]. Chirurg 1970;41:511-515.
28. Klemm K. [Gentamicin-PMMA-beads in treating bone and soft tissue infections (author's trans.)]. Zentralbl Chir. 1979; 104:934-942.
29. Henry SL, Galloway KP. Local antibacterial therapy for the management of orthopaedic infections: Pharmacokinetic considerations. Clin Pharmacokinet. 1995;29:36-45.
30. Wininger DA, Fass RJ. Antibiotic-impregnated cement and beads for orthopedic infections. Antimicrob Agents Chemother. 1996;40:2675-2679.
31. Adams K, Couch L, Cierny G, Calhoun J, Mader JT. In vitro and in vivo evaluation of antibiotic diffusion from antibioticimpregnated polymethylmethacrylate beads. Clin Orthop Relat Res. 1992;278:244-252.
32. Wahlig H, Dingeldein E. Antibiotics and bone cements: Experimental and clinical long-term observations. Acta Orthop Scand. 1980;51:49-56.
33. Bowyer GW, Cumberland N. Antibiotic release from impregnated pellets and beads. J Trauma 1994;36:331-335.
34. Cornell CN, Tyndall D, Waller S, Lane JM, Brause BD. Treatment of experimental osteomyelitis with antibiotic-impregnated bone graft substitute. J Orthop Res. 1993;11:619-626.
35. Garvin KL, Miyano JA, Robinson D, Giger D, Novak J, Radio S. Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis: A canine model. J Bone Joint Surg Am. 1994;76:1500-1506.
36. Cierny G III, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Contemp Orthoped. 1985;10:17-37.
37. Cierny G III, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003;414:7-24.
38. Cierny G III, Mader JT. The surgical treatment of adult osteomyelitis. In: Evarts CM, ed. Surgery of the Musculoskeletal System. 2nd ed. New York: Churchill Livingston; 1983:4814-4834.
39. Court-Brown CM, Keating JF, McQueen MM. Infection after intramedullary nailing of the tibia: Incidence and protocol for management. J Bone Joint Surg Br. 1992;74:770-744.
40. Mousa HA. Evaluation of sinus-track cultures in chronic bone infection. J Bone Joint Surg Br. 1997;79:567-569.
41. Wheat J. Diagnostic strategies in osteomyelitis. Am J Med. 1985;78:218-224.
42. Ziran BH, Rao N, Hall RA. A dedicated team approach enhances outcomes of osteomyelitis treatment. Clin Orthop Relat Res. 2003;414:31-36.
43. Ilizarov GA. The treatment of pseudarthrosis complicated by osteomyelitis and the elimination of purulent cavities. In: The Transosseous Osteosynthesis: Theoretical and Clinical Aspects of the Regeneration and Growth of Tissue. Berlin: Springer-Verlag; 1993:495-547.
44. Decoster TA, Bozorgnia S. Antibiotic beads. J Am Acad Orthop Surg. 2008;16:674-678.
45. Green SA. Osteomyelitis: The Ilizarov perspective. Orthop Clin North Am. 1991;22:515-521.
46. Marsh DR, Shah S, Elliott J, Kurdy N. The Ilizarov method in nonunion, malunion and infection of fractures. J Bone Joint Surg Br. 1997;79:273-279.
47. Galkowska H, Podbielska A, Olszewski WL, et al. Epidemiology and prevalence of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis in patients with diabetic foot ulcers: Focus on the differences between species isolated from individuals with ischemic vs. neuropathic foot ulcers. Diabetes Res Clin Pract. 2009;84:187-193.
48. Tentolouris N, Petrikkos G, Vallianou N, et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect. 2006;12: 186-189.
49. Varaiya AY, Dogra JD, Kulkarni MH, Bhalekar PN. Extendedspectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot infections. Indian J Pathol Microbiol. 2008;51:370-372.
50. Yates C, May K, Hale T, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care 2009;32:1907-1909.
51. Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis. 2004;39(Suppl. 2):S115-S122.
52. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004; 39:885-910.
53. Berendt AR, Peters EJ, Bakker K, et al. Diabetic foot osteomyelitis: A progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008; 24(Suppl. 1):S145-S161.
54. Goldman RJ. Hyperbaric oxygen therapy for wound healing and limb salvage: A systematic review. PM R. 2009;1:471-489.
55. Fang RC, Galiano RO. Adjunctive therapies in the treatment of osteomyelitis. Semin Plastic Surg. 2009;23:141-147.
56. Rennert R, Golinko M, Yan A, et al. Developing and evaluating outcomes of an evidence-based protocol for the treatment of osteomyelitis in stage IV pressure ulcers: A literature and wound electronic medical record database review. Ostomy Wound Manage. 2009;55:42-53.
57. Han H, Lewis VI Jr, Wiedrich TA, et al. The value of Jamshidi core needle bone biopsy in predicting postoperative osteomyelitis in grade IV pressure ulcer patients. Plast Reconstr Surg. 2002;110:118-122.
58. Marriott R, Rubayi S. Successful truncated osteomyelitis treatment for chronic osteomyelitis secondary to pressure ulcers in spinal cord injury patients. Ann Plast Surg. 2008; 61:425-429.